PC

(redirected from 486)
Also found in: Dictionary, Thesaurus, Legal, Financial, Acronyms, Encyclopedia, Wikipedia.

PC

phosphocreatine.

PC

1 abbreviation for professional corporation.
2 abbreviation for personal computer.
3 abbreviation for the Latin post cibum, 'after meals.'

PC

Abbreviation for:
packed (red) cells
paper chromatography, see there
paracortical hyperplasia
parent care
parent cells
Parish Council   
patient choice (NHS Choices)
Patients’ Council 
peak capacity
penetrating cell
pentose cycle
pericarditis
pericentral
peripheral cell
personal computer
phaeochromocytoma
phenol coefficient
phobia clinic
phosphatidylcholine (lecithin)
phosphate cycle
phosphocholine
phosphocreatinine
phosphorylcholine
physocyanin
plasma cell
plasmacytoma
platelet concentrate
platelet count
pneumotaxic centre
pocket computer
politically correct
polycarbonate
polycarbosilane
Population Council
portable computer
portocaval
post cibum
postcoital
posterior chamber Ophthalmology
posterior commissure Neuroanatomy
postinflammatory corticosteroid
precaution category (Lab medicine)
precordia Anatomy
present complaint
primary care, see there
primary circuit
procarbazine
professional corporation
propylene carbonate
provocative concentration (Immunology)
pseudoconditioning control (Neurophysiology)
public convenience (UK)
pubococcygeus
pulmonary capillary
pulmonary (valve) closure
Purkinje cells (Neuroanatomy)
pyruvate carboxylase

PC

1. Packed cells–RBCs.
2. Personal computer, see PC 3. Plasma cell 4. Politically correct 5. Present complaint 6. Professional corporation.

PC

Abbreviation for Pneumocystis carinii.

PC

Abbrev. for Pharmaceutical Chemist.

PC,

n pericardium channel; an acupuncture channel that runs from the shoulder to the hand along the medial surface of the arm, named after the pericardium, and associated with the triple burner (TE) channel. See also TE.
References in periodicals archive ?
Another safeguard that came under attack was how far along in pregnancy a woman could be and still use RU 486.
Remaining rights to RU 486 were supposed to have been transferred to Sakiz and Exelgyn once Roussel Uclaf decided to distance itself from the controversial drug in 1997.
Ware said that among Exelgyn's conditions for introducing RU 486 into a country were strict distribution controls and the availability of medical and surgical care, presumably to handle serious complications that women may experience after taking the drug.
The report has the Beverly Winikoff, program director for the Population Council, asserting that approximately 500,000 women worldwide have used the combination of RU 486 and a prostaglandin to abort their babies.
Delegates see RU 486 as part of an increasingly abortion-saturated culture.
Against that prediction is the fact that the number of abortions has been declining in the United States and RU 486 still does not have final FDA approval.
Because alternative abortion methods exist, no novel or urgent medical situation is present that requires FDA to expedite review or approval of an NDA for RU 486 as an abortifacient.
The availability of alternative abortion methods should be considered by FDA in performing a risk/benefit evaluation of RU 486 as an abortifacient.
1) FDA audit all foreign data submitted in support of any NDA for RU 486 as an abortifacient;
2) No NDA for RU 486 as an abortifacient be approved by FDA unless the safety and efficacy concerns presented in this petition are adequately resolved;
3) FDA not approve RU 486 in the absence of clinical and nonclinical data that fully evaluate the potential adverse effects on the health of women who take RU 486 and/or misoprostol and any children born after exposure to these drugs;
A French pharmaceutical firm (Roussel Uclaf Company) developed RU 486 in the 1980s.